(PharmaNewsWire.Com, July 09, 2017 ) Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of skin and the whites of eyes (jaundice) , loss of appetite, weight loss, depression and blood clots. Predisposing factors include age, gender, smoking, diabetes and family history. Treatment includes surgery, chemotherapy and radiation therapy.
Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Pancreatic Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Pancreatic Cancer (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Pancreatic Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pancreatic Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 16, 120, 121, 2, 8, 273, 36 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 20, 9, 52 and 6 molecules, respectively.
Pancreatic Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatic Cancer (Oncology) . - The pipeline guide reviews pipeline therapeutics for Pancreatic Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Pancreatic Cancer (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Pancreatic Cancer (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatic Cancer (Oncology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Pancreatic Cancer (Oncology) . - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Pancreatic Cancer (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Key Company profiles 3-V Biosciences Inc 4P-Pharma SAS AB Science SA AbbVie Inc AbGenomics International Inc Ability Pharmaceuticals SL Actuate Therapeutics Inc Adamed Sp z oo Aduro BioTech Inc Advanced Cancer Therapeutics LLC Advantagene Inc Agenus Inc AGV Discovery SAS AIMM Therapeutics BV Alissa Pharma Allinky Biopharma Almac Discovery Ltd Altor BioScience Corp Ambrx Inc amcure GmbH American Gene Technologies International Inc Amgen Inc Anavex Life Sciences Corp Andarix Pharmaceuticals Inc ANP Technologies Inc AntiCancer Inc APEIRON Biologics AG Aphios Corp APIM Therapeutics AS Apogenix GmbH Aposense Ltd ARMO Biosciences Inc ArQule Inc Array BioPharma Inc Astellas Pharma Inc AstraZeneca Plc Aurigene Discovery Technologies Ltd Autotelic Inc AVEO Pharmaceuticals Inc Axcentua Pharmaceuticals AB Basilea Pharmaceutica Ltd Bavarian Nordic A/S Bayer AG BeiGene (Beijing) Co Ltd Bellicum Pharmaceuticals Inc Berg LLC BerGenBio ASA Beta Pharma Inc Bexion Pharmaceuticals LLC BeyondSpring Pharmaceuticals Inc Bio-Path Holdings Inc BioLineRx Ltd Biomar Microbial Technologies Biomunex Pharmaceuticals Bioncotech Therapeutics SL Bionomics Ltd BioNTech AG Biotest AG Biouniversa srl BLR Bio LLC Boehringer Ingelheim GmbH Boston Biomedical Inc Bristol-Myers Squibb Company Cadila Pharmaceuticals Ltd Calithera Biosciences Inc Cancer Prevention Pharmaceuticals Inc Cantargia AB Cascadian Therapeutics Inc Cavion LLC CBT Pharmaceuticals Inc CCRP Therapeutics GmbH Celgene Corp Celleron Therapeutics Ltd Cellular Biomedicine Group Inc Celprogen Inc Celyad SA Centrose LLC Ceronco Biosciences ChemoCentryx Inc Chugai Pharmaceutical Co Ltd Clovis Oncology Inc COARE Biotechnology Inc Codiak BioSciences Inc Concordia International Corp Confluence Life Sciences Inc Critical Outcome Technologies Inc CrystalGenomics Inc CTI BioPharma Corp Cyclacel Pharmaceuticals Inc CytomX Therapeutics Inc Cytori Therapeutics Inc CytRx Corp CyTuVax BV Daewoong Pharmaceutical Co Ltd Daiichi Sankyo Company Ltd DEKK-TEC Inc Denceptor Therapeutics Ltd Diffusion Pharmaceuticals Inc Eisai Co Ltd Eleison Pharmaceuticals LLC Eli Lilly and Company Endor Nanotechnologies SL Ensemble Therapeutics Corp Ensol Biosciences Inc Erytech Pharma SA Esperance Pharmaceuticals Inc Etubics Corp Exelixis Inc F. Hoffmann-La Roche Ltd Faron Pharmaceuticals Oy FibroGen Inc Formosa Laboratories Inc Forty Seven Inc Fountain Biopharma Inc Fujifilm Corp
List of Tables Number of Products under Development for Pancreatic Cancer, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..2) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..3) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..4) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..5) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..6) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..7) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..8) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..9) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..10) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..11) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..12) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..13) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..14) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..15) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..16) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..17) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..18) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..19) , H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..20) , H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2) , H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 (Contd..3) , H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1) , H1 2017 Products under Development by Companies, H1 2017 (Contd..2) , H1 2017 Products under Development by Companies, H1 2017 (Contd..3) , H1 2017 Products under Development by Companies, H1 2017 (Contd..4) , H1 2017 Products under Development by Companies, H1 2017 (Contd..5) , H1 2017 Products under Development by Companies, H1 2017 (Contd..6) , H1 2017 Products under Development by Companies, H1 2017 (Contd..7) , H1 2017 Products under Development by Companies, H1 2017 (Contd..8) , H1 2017 Products under Development by Companies, H1 2017 (Contd..9) , H1 2017 Products under Development by Companies, H1 2017 (Contd..10) , H1 2017 Products under Development by Companies, H1 2017 (Contd..11) , H1 2017 Products under Development by Companies, H1 2017 (Contd..12) , H1 2017 Products under Development by Companies, H1 2017 (Contd..13) , H1 2017 Products under Development by Companies, H1 2017 (Contd..14) , H1 2017 Products under Development by Companies, H1 2017 (Contd..15) , H1 2017 Products under Development by Companies, H1 2017 (Contd..16) , H1 2017 Products under Development by Companies, H1 2017 (Contd..17) , H1 2017 Products under Development by Companies, H1 2017 (Contd..18) , H1 2017 Products under Development by Companies, H1 2017 (Contd..19) , H1 2017 Products under Development by Companies, H1 2017 (Contd..20) , H1 2017 Products under Development by Companies, H1 2017 (Contd..21) , H1 2017 Products under Development by Companies, H1 2017 (Contd..22) , H1 2017 Products under Development by Companies, H1 2017 (Contd..23) , H1 2017 Products under Development by Companies, H1 2017 (Contd..24) , H1 2017 Products under Development by Companies, H1 2017 (Contd..25) , H1 2017 Products under Development by Companies, H1 2017 (Contd..26) , H1 2017 Products under Development by Companies, H1 2017 (Contd..27) , H1 2017 Products under Development by Companies, H1 2017 (Contd..28) , H1 2017 Products under Development by Companies, H1 2017 (Contd..29) , H1 2017 Products under Development by Companies, H1 2017 (Contd..30) , H1 2017 Products under Development by Companies, H1 2017 (Contd..31) , H1 2017 Products under Development by Universities/Institutes, H1 2017 Products under Development by Universities/Institutes, H1 2017 (Contd..1) , H1 2017 Products under Development by Universities/Institutes, H1 2017 (Contd..2) , H1 2017 Products under Development by Universities/Institutes, H1 2017 (Contd..3) , H1 2017 Products under Development by Universities/Institutes, H1 2017 (Contd..4) , H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..2) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..3) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..4) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..5) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..6) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..7) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..8) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..9) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..10) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..11) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..12) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..13) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..14) , H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..15) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..9) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..10) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..11) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..12) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..13) , H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..14) , H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pancreatic Cancer - Pipeline by 3-V Biosciences Inc, H1 2017 Pancreatic Cancer - Pipeline by 4P-Pharma SAS, H1 2017 Pancreatic Cancer - Pipeline by AB Science SA, H1 2017 Pancreatic Cancer - Pipeline by AbbVie Inc, H1 2017 Pancreatic Cancer - Pipeline by AbGenomics International Inc, H1 2017 Pancreatic Cancer - Pipeline by Ability Pharmaceuticals SL, H1 2017 Pancreatic Cancer - Pipeline by Actuate Therapeutics Inc, H1 2017 Pancreatic Cancer - Pipeline by Adamed Sp z oo, H1 2017 Pancreatic Cancer - Pipeline by Aduro BioTech Inc, H1 2017 Pancreatic Cancer - Pipeline by Advanced Cancer Therapeutics LLC, H1 2017 Pancreatic Cancer - Pipeline by Advantagene Inc, H1 2017 Pancreatic Cancer - Pipeline by Agenus Inc, H1 2017 Pancreatic Cancer - Pipeline by AGV Discovery SAS, H1 2017 Pancreatic Cancer - Pipeline by AIMM Therapeutics BV, H1 2017 Pancreatic Cancer - Pipeline by Alissa Pharma, H1 2017 Pancreatic Cancer - Pipeline by Allinky Biopharma, H1 2017 Pancreatic Cancer - Pipeline by Almac Discovery Ltd, H1 2017 Pancreatic Cancer - Pipeline by Altor BioScience Corp, H1 2017 Pancreatic Cancer - Pipeline by Ambrx Inc, H1 2017 Pancreatic Cancer - Pipeline by amcure GmbH, H1 2017 Pancreatic Cancer - Pipeline by American Gene Technologies International Inc, H1 2017 Pancreatic Cancer - Pipeline by Amgen Inc, H1 2017 Pancreatic Cancer - Pipeline by Anavex Life Sciences Corp, H1 2017 Pancreatic Cancer - Pipeline by Andarix Pharmaceuticals Inc, H1 2017 Pancreatic Cancer - Pipeline by ANP Technologies Inc, H1 2017 Pancreatic Cancer - Pipeline by AntiCancer Inc, H1 2017 Pancreatic Cancer - Pipeline by APEIRON Biologics AG, H1 2017 Pancreatic Cancer - Pipeline by Aphios Corp, H1 2017 Pancreatic Cancer - Pipeline by APIM Therapeutics AS, H1 2017 Pancreatic Cancer - Pipeline by Apogenix GmbH, H1 2017 Pancreatic Cancer - Pipeline by Aposense Ltd, H1 2017 Pancreatic Cancer - Pipeline by ARMO Biosciences Inc, H1 2017 Pancreatic Cancer - Pipeline by ArQule Inc, H1 2017 Pancreatic Cancer - Pipeline by Array BioPharma Inc, H1 2017 Pancreatic Cancer - Pipeline by Astellas Pharma Inc, H1 2017 Pancreatic Cancer - Pipeline by AstraZeneca Plc, H1 2017 Pancreatic Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H1 2017 Pancreatic Cancer - Pipeline by Autotelic Inc, H1 2017 Pancreatic Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2017 Pancreatic Cancer - Pipeline by Axcentua Pharmaceuticals AB, H1 2017 Pancreatic Cancer - Pipeline by Basilea Pharmaceutica Ltd, H1 2017 Pancreatic Cancer - Pipeline by Bavarian Nordic A/S, H1 2017 Pancreatic Cancer - Pipeline by Bayer AG, H1 2017 Pancreatic Cancer - Pipeline by BeiGene (Beijing) Co Ltd, H1 2017 Pancreatic Cancer - Pipeline by Bellicum Pharmaceuticals Inc, H1 2017 Pancreatic Cancer - Pipeline by Berg LLC, H1 2017 Pancreatic Cancer - Pipeline by BerGenBio ASA, H1 2017 Pancreatic Cancer - Pipeline by Beta Pharma Inc, H1 2017 Pancreatic Cancer - Pipeline by Bexion Pharmaceuticals LLC, H1 2017 Pancreatic Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2017 Pancreatic Cancer - Pipeline by Bio-Path Holdings Inc, H1 2017 Pancreatic Cancer - Pipeline by BioLineRx Ltd, H1 2017 Pancreatic Cancer - Pipeline by Biomar Microbial Technologies, H1 2017 Pancreatic Cancer - Pipeline by Biomunex Pharmaceuticals, H1 2017 Pancreatic Cancer - Pipeline by Bioncotech Therapeutics SL, H1 2017 Pancreatic Cancer - Pipeline by Bionomics Ltd, H1 2017 Pancreatic Cancer - Pipeline by BioNTech AG, H1 2017 Pancreatic Cancer - Pipeline by Biotest AG, H1 2017 Pancreatic Cancer - Pipeline by Biouniversa srl, H1 2017 Pancreatic Cancer - Pipeline by BLR Bio LLC, H1 2017 Pancreatic Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2017 Pancreatic Cancer - Pipeline by Boston Biomedical Inc, H1 2017 Pancreatic Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2017 Pancreatic Cancer - Pipeline by Cadila Pharmaceuticals Ltd, H1 2017 Pancreatic Cancer - Pipeline by Calithera Biosciences Inc, H1 2017 Pancreatic Cancer - Pipeline by Cancer Prevention Pharmaceuticals Inc, H1 2017
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
